ERAS and neoplasm: To evaluate the roles of ARF activation and ERAS disruption in tumour resistance in NMR-iPSCs, we introduced short hairpin RNAs targeting ARF (shARF) and/or Ms-ERas (mERas) into NMR-iPSCs (shARF-, mERas- or shARF/mERas-NMR-iPSCs).